Allergy/Immunology
RSSArticles
-
Preventing SARS-CoV-2 Infection with an Allergy Nasal Spray
Use of the antihistamine azelastine nasal spray was effective in preventing SARS-CoV-2 infection in young, healthy, vaccinated outpatients.
-
Patients Aged 6 Months and Older with Egg Allergy Should Receive Flu Vaccine
The Advisory Committee on Immunization Practices (ACIP) provided updated guidance for the 2025-2026 influenza season. After reviewing data on egg-based influenza vaccines, ACIP reinforced that individuals with egg allergies are not at increased risk of severe allergic reactions and outlined precaution and contraindication considerations in vaccine administration for this population.
-
Evaluation and Management of Anaphylaxis in the Emergency Department
This article will present the most current information for diagnosing allergic reactions and anaphylaxis and how to treat them properly.
-
Epinephrine Nasal Spray (Neffy)
The U.S. Food and Drug Administration has approved epinephrine nasal spray for the emergency treatment of allergic reactions, including anaphylaxis. It was granted a fast-track designation and will be distributed by ARS Pharmaceuticals as Neffy.
-
Oral Penicillin Challenge vs. Skin Testing: Diagnosing Low-Risk Patients with Reported Penicillin Allergy
In a comparison of direct oral penicillin challenge in low-risk patients to skin testing followed by oral challenge, researchers reported no significant differences. Direct oral penicillin challenge appears to be a safe and effective way to delabel a penicillin allergy.
-
Managing Anaphylaxis in the Emergency Department
The incidence of anaphylaxis, a rapidly progressive and potentially fatal disease, is increasing and unfortunately common in children. It is imperative that all acute care providers are prepared to recognize, quickly treat, and ensure appropriate follow-up for these patients. The authors focus on anaphylaxis, its presentation, management, and disposition from the ED.
-
Researchers Address HIV Treatment Gap Among Underserved Population
There are effective medications, but social determinants of health can dictate adherence.
-
Smallpox and Monkeypox Vaccine, Live, Non-Replicating (Jynneos)
Jynneos can be administered to prevent smallpox and monkeypox in adults age 18 years and older who are at high risk for contracting the infections.
-
COVID-19 and Headache
Headache is a common feature of acute COVID-19 infection, as well as a long-standing feature of “long COVID” after recovery from the acute infection. Treatment is symptomatic, based on the characteristics of the headache syndrome.
-
Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373)
Novavax is authorized to be administered to patients age 18 years and older for active immunization to prevent COVID-19 caused by SARS-CoV-2.